Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
October 19 2023 - 8:00AM
Business Wire
- Seasoned biotechnology executive and
board-certified physician in medical oncology joins executive team
as Immunome advances growing pipeline of cancer therapies -
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced the appointment of Bob Lechleider, M.D.,
as Chief Medical Officer. Dr. Lechleider brings over 20 years of
experience as an academic and industry executive in medical
oncology and cancer research.
“We are delighted to welcome Bob to our team during an exciting
time in Immunome’s growth as we focus on advancing our oncology
pipeline into the clinic,” said Dr. Siegall, President and Chief
Executive Officer of Immunome. “Bob’s extensive experience in both
early and late-stage oncology programs, including the successful
initial licensing of Padcev®, an antibody-drug conjugate for the
treatment of urothelial cancer, is expected to add significant
value to Immunome’s vision of developing first-in-class and
best-in-class targeted cancer therapies for patients.”
“I am thrilled to be joining the Immunome team at such an
exciting time in the company’s story. I would like to extend my
thanks to Dr. Siegall and the entire Immunome team for welcoming me
to the company,” said Bob Lechleider, M.D., Chief Medical Officer
of Immunome. “I look forward to working with the Immunome
management and scientific leadership to develop a preeminent
clinical organization to advance development of our diverse
pipeline of small molecule, antibody drug conjugate and targeted
effector candidates, with the ultimate goal of shifting the
treatment paradigm for patients with cancer.”
Prior to joining Immunome, Dr. Lechleider was the Chief Medical
Officer at OncoResponse, where he oversaw the development of the
company’s proprietary oncology pipeline. Before OncoResponse, Dr.
Lechleider served as the Senior Vice President of clinical
development for Seagen, where he was responsible for directing the
development of the early and late-stage portfolios, including the
successful initial licensing of Padcev® for the treatment of
previously treated metastatic urothelial cancer.
Dr. Lechleider began his biotech career at MedImmune (an Astra
Zeneca company) and went on to positions of increasing
responsibility at Human Genome Sciences and Macrogenics before
heading development at Seagen. Prior to his career in biotech, Dr.
Lechleider held academic positions where he studied basic cellular
and molecular biology.
Dr. Lechleider earned his A.B. from Princeton University and his
M.D. from the University of Illinois College of Medicine at Chicago
before receiving his clinical residency in internal medicine at
Beth Israel-Deaconess Medical Center in Boston, and later in
medical oncology at the National Cancer Institute (NCI) in
Bethesda.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including immunotherapies, targeted effectors, radioligand
therapies and ADCs. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). These include, but are
not limited to, statements regarding Immunome’s intent to advance
its current pipeline into the clinic, to develop first-in-class and
best-in-class targeted cancer therapies for patients ; and other
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Immunome undertakes no obligation
to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise, except to
the extent required by law. We use words such as “expect,” “look
forward to,” “goal,” and other similar expressions to identify
these forward-looking statements that are intended to be covered by
the safe-harbor provisions of the PSLRA. Such forward-looking
statements are based on our expectations and involve risks and
uncertainties; consequently, actual results may differ materially
from those expressed or implied in the statements due to a number
of factors, including, but not limited to, the ability of Immunome
to grow and successfully execute on its business plan, including
advancing its current pipeline into the clinic and expanding its
pipeline through its technology platform, proprietary toolbox as
and when anticipated, and through strategic transactions, if any;
changes in the applicable laws or regulations; the possibility that
Immunome may be adversely affected by other economic, business,
and/or competitive factors; the risk that regulatory approvals for
Immunome’s programs and product candidates are not obtained, are
delayed or are subject to unanticipated conditions that could
adversely affect it; Immunome’s ability to manage clinical trials
or studies; the risk that pre-clinical data may not be predictive
of clinical data; the complexity of numerous regulatory and legal
requirements that Immunome needs to comply with to operate its
business; the reliance on Immunome’s management and the fact that
the prior experience and successes of the Immunome’s management
team are not indicative of any future success for Immunome;
uncertainties related to Immunome’s capital requirements and
Immunome’s expected cash runway; the failure to obtain, adequately
protect, maintain or enforce Immunome’s intellectual property
rights; and other risks and uncertainties indicated from time to
time described in Immunome’s Annual Report on Form 10-K for the
year ended December 31, 2022, and in Immunome’s other filings with
the SEC. Immunome cautions that the foregoing list of factors is
not exclusive and not to place undue reliance upon any
forward-looking statements which speak only as of the date made.
Moreover, Immunome operates in a very competitive and rapidly
changing environment. New risks emerge from time to time. Except as
required by law, Immunome does not undertake any obligation to
update publicly any forward-looking statements for any reason after
the date of this press release to conform these statements to
actual results or to changes in their expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019764748/en/
Investor Contact Corleen Roche Chief Financial Officer
investors@immunome.com
Media Contact Andrew W. Mielach LifeSci Communications
amielach@lifescicomms.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024